TCM
FOLD

Traynor Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Traynor Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,346
Closed -$223K – 165
2017
Q1 		$223K Buy
+29,346
New +$186K 0.12% 133

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Traynor Capital Management's FOLD Position: Q2 2017 in Review

Traynor Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2017, closing a stake of 29,346 shares — an estimated $223K sold.

Traynor Capital Management first reported a position in FOLD in Q1 2017 and held it in 1 quarter. The position peaked at $223K in Q1 2017. 141 funds tracked by Wall St. Rank hold FOLD as of Q2 2017.

  • Traynor Capital Management reported no remaining Amicus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Traynor Capital Management sold 29,346 Amicus Therapeutics shares in Q2 2017, an estimated $223K.
  • Traynor Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 1 quarter.
  • Traynor Capital Management's Amicus Therapeutics position peaked at $223K in Q1 2017.
  • 141 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2017.

Based on Traynor Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.